Antelope Dx is a Belgium-based biotechnology startup that is revolutionizing home diagnostics with its flagship product—a compact, handheld medical testing tool. Founded in 2018, the company seeks to combine the accuracy of lab-grade diagnostics with the convenience and affordability of consumer-grade tests, akin to pregnancy kits.
Antelope Dx's device offers rapid and accessible health assessments, positioning itself as an invaluable tool for both individuals and healthcare providers. This innovation addresses a critical niche in the burgeoning remote and connected healthcare landscape.
The company secured a €9.00M Series B investment on 15 September 2020, showcasing confidence from investors like Saffelberg Investments, White Fund, and RMM. These funds aim to propel Antelope Dx's growth trajectory, facilitating further development and market penetration of its diagnostic platform.